FDA Inspection 1308808 — Saving Sight
The FDA completed an inspection of Saving Sight on February 25, 2026 in Kansas City, MO. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Biologics.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- February 25, 2026
- Fiscal Year
- 2026
- Product Type
- Biologics
- Project Area
- Human Cellular, Tissue, and Gene Therapies
- Location
- Kansas City, MO (United States)